Refractory Livedoid Vasculopathy: Clinical Response to TNF-α Blocker in a Young Male Patient.
DOI:
https://doi.org/10.70672/jym8d336Keywords:
Adalimumab, Anticoagulant Antiplatelet, Corticosteroid, Livedoid vasculopathy, Refractory, Thrombosis, Vasculitis, Vasodilator.Abstract
Livedoid vasculopathy is a rare condition characterized by thrombosis of dermal vessels, predominantly affecting the ankles. The patient presented with a painful ulcer, which is usually chronic in nature with relapsing-remitting episodes. It may resemble other vasculitides disorders, such as microscopic polyangiitis and polyarteritis nodosa. Hence, diagnosis is mainly based on clinical and histopathological findings. Livedoid vasculopathy required antiplatelet and anticoagulant therapy, in contrast to vasculitides disorders. We describe a young man who presented with a recent onset of painful ulcers on both ankle regions, consistent with livedoid vasculopathy and supported by histopathological findings. Clinical remission was observed after treatment with subcutaneous adalimumab, after failing to respond to a combination of anticoagulant, corticosteroid, vasodilator, and antiplatelet agents.
References
[1]. Milian MG. Les atrophies cutaneìes syphilitiques. Bull Soc Franc Derm Syph. 1929;36:865–71.
[2]. Gardette E, Moguelet P, Bouaziz JD, Lipsker D, Dereure O, Le Pelletier F, et al. Livedoid vasculopathy: a french observational study including therapeutic options. Acta Derm Venereol. 2018;98:842–7.
[3]. Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol. 2016; 3:e72–9.
[4]. Criado PR, Rivitti EA, Sotto MN, de Carvalho JF. Livedoid vasculopathy as a coagulation disorder. Autoimmun Rev 2011;10:353–360.
[5]. Alavi A, Hafner J, Dutz JP, Mayer D, Sibbald RG, Criado PR, et al. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach. J Am Acad Dermatol. 2013;69:1033–42.e1.
[6]. Freitas TQ, Halpern I, Criado PR . Livedoid vasculopathy: A compelling diagnosis. Au- tops Case Rep 2018;8: e2018034.
[7]. Gao Y, Jin H. Livedoid vasculopathy and its association with genetic variants: a systematic review. Int Wound J. 2021;18: 616–25.
[8]. Criado PR, Rivitti EA, Sotto MN, Valente NY, Aoki V, Carvalho JF, et al. Livedoid vasculopathy: an intringuing cutaneous disease. An Bras Dermatol. 2011;86:961–77
[9]. Micieli R, Alavi A. Treatment for Livedoid Vasculopathy: A Systematic Review. JAMA Dermatol. 2018;154:193-202.
[10]. Lee JH, Choi HJ, Kim SM, Hann SK, Park YK. Livedoid vasculitis responding to PUVA therapy. Int J Dermatol. 2001;40:153-7.
[11]. Huang XW, Zheng HX, Wang ML, He WM, Feng MX, Zeng K et al. Adalimumab in Treating Refractory Livedoid Vasculopathy. Vaccines (Basel). 2022;10:549.
[12]. Bhatt DM, Bhamburkar S, Madke B, Jangid SD, Khan A. Adalimumab in the Treatment of Recalcitrant Livedoid Vasculopathy. Cureus. 2023;15:e50053.
[13]. Gao Y, Jin H. Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis. Journal of Dermatological Treatment. 2020;33: 178–183.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medicine & Health Sciences

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Engineering Technology (JET) is an open-access journal that follows the Creative Commons Attribution-Non-commercial 4.0 International License (CC BY-NC 4.0)



